The acquisition will help PerkinElmer expand its infectious disease testing portfolio to include tuberculosis detection, giving it access to Oxford Immunotec's T-cell immunology technology for testing latent tuberculosis, it said.

Oxford Immunotec reported total revenue of U.S. $73.7 million in fiscal year 2019 and U.S. $39.2 million in the nine months ended September 30, 2020.

Once the deal closes, Oxford Immunotec will become a privately held firm, PerkinElmer said.